NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search by Keyword field to narrow your search.

Showing results filtered by:

The Accelerating Medicines Partnership is a public-private collaboration among the National Institutes of Health, pharmaceutical companies, and non-profit organizations.

This program aims to advance novel vaccine adjuvants toward licensure for human use. The program supports the optimization of adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.

The AADCRC program is the cornerstone of NIAID efforts to promote multidisciplinary basic and clinical research on the immunological basis, pathobiology, diagnosis, treatment, and preven​tion of asthma and allergic diseases.

The Atopic Dermatitis Research Network is a consortium of academic medical centers that conduct clinical research studies in an attempt to learn more about skin infections associated with atopic dermatitis.

The ACEs conduct collaborative basic and clinical research on autoimmune diseases. Close interaction between clinicians and basic researchers accelerates the discovery, development, and translation of therapies for autoimmune diseases from the lab to use in the clinic.

The Clinical Islet Transplantation Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.

The Clinical Trials in Organ Transplantation (CTOT) program is an investigative consortium that conducts clinical and associated mechanistic studies to improve outcomes for transplant recipients.

The Clinical Trials in Organ Transplantation in Children (CTOT-C) program focuses on the specific challenges associated with pediatric organ transplantation. This program is a continuation of the first NIAID pediatric transplantation clinical trial consortium, the Cooperative Clinical Trials in Pediatric Transplantation program.

The Consortium of Food Allergy Research (CoFAR) was established in fiscal year (FY) 2005 to support clinical research on food allergy. It was renewed in FY 2010 to continue several promising clinical studies from the original consortium and expanded to include research on the genetic causes underlying food allergy and the mechanisms of food allergy-associated eosinophilic esophagitis.

The long-term goal of the Cooperative Centers on Human Immunology (CCHI) program is the translation of immunology research into clinical applications in humans in the area of infectious disease.

This purpose of this program is to understand how the human leukocyte antigen (HLA) gene region and killer immunoglobulin-like receptor gene family are associated with immune-mediated diseases.

The Human Immunology Project Consortium (HIPC) is a network of researchers established to create a public resource that characterizes the diverse states of the human immune system. HIPC investigators use modern analytic tools to profile the immune system before and after infection, vaccination, or treatment with an adjuvant.

Co-sponsored by NIAID and the Juvenile Diabetes Research Foundation International, the ITN is an international consortium of basic scientists and clinical investigators that performs clinical research to evaluate the safety and efficacy of methods that can induce the immune system to tolerate certain antigens for the treatment of immune-mediated disorders.

The Immunity in Neonates and Infants Program supports research of the developing immune system during the first year of life. This program encourages the use of innovative approaches using human infant tissues and cells, or relevant animal models, to define pathways and mechanisms that contribute to the immune status of the neonate and infant.

The Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP) aims to develop preclinical porcine to nonhuman primate models of islet, kidney, heart, lung, or liver xenotransplantation.

The primary clinical goals of this multi-center clinical trial on HIV+ kidney transplant recipients are to evaluate the impact of CCR5 blockade (maraviroc, MVC) on renal function at week 52 post-transplant; as well as evaluate the overall safety and tolerability of CCR5 blockade in the HIV+ kidney transplant recipient.

Inner-City Asthma Consortium (ICAC) focuses on understanding how the environment, allergens, and genetics interact with the body’s immune system to cause asthma and aggravate its symptoms.

The NIAID Modeling Immunity for Biodefense (MIB) program brings together immunologists, microbiologists, bioinformaticians, and modelers to advance our understanding of the complex immune mechanisms triggered by infection and/or vaccination.

This program supports the discovery and analysis of combination adjuvants. Combining different adjuvants can improve the immune response that a vaccine induces and the protection it provides. However, little is known about how to best combine different adjuvants to optimize vaccine efficacy.

CSGADP was established in 2001 as a collaborative network of investigators with a focus on halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression with an emphasis on Type 1 diabetes.

The Systems Approach to Immunity and Inflammation Program conducts forward genetic screens of mutant or genetically diverse mice, combined with systems level analysis, to identify previously unappreciated key immune regulatory genes, signaling pathways, or mechanisms; and includes validation of these pathways in human cells and tissues.

This program supports novel T-cell epitope identification, characterization and validation of important food allergens and aeroallergens that have not been previously studied.

The United States Immunodeficiency Network, a NIH-funded research program of the Immune Deficiency Foundation, was established to advance scientific research in primary immunodeficiency (PI) diseases.